The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.

BACKGROUND AND AIMS The thiopurine drugs, azathioprine (AZA) and 6-mercaptopurine, are established in the treatment of inflammatory bowel diseases (IBD). Polymorphisms in thiopurine S-methyltransferase (TPMT) gene have been associated with adverse drug reactions (ADRs) to AZA. METHODS The aim of this study was to evaluate TPMT polymorphisms and AZA-related toxicity in a Slovak cohort of 220 IBD patients treated with AZA. In every patient, the dose and duration of AZA therapy, concomitant 5-aminosalicylate (5-ASA) medication, frequency, type, time to onset, dose of ADR and concomitant 5-ASA at the onset of ADR were recorded. Each patient was also genotyped for the presence of variant TPMT alleles (*2,*3A,*3B,*3C). Frequency, type and circumstances of ADRs were compared according to TPMT status. RESULTS Of the 220 patients, 205 (93.2 %) were wild-type (TPMT*1/*1), one (0.5%) carried a TPMT*1/*3C allele, 13 (5.9 %) carried TPMT *1/*3A allele and one was homozygous for TMPT *3A allele. No TPMT *2 mutation was found. The incidence of adverse drug reactions was 62/205 (30.2 %) in the wild-type group as compared to 13/15 (86.7 %) in the TPMT mutation group, p=2.10-5. Leukopenia (WBC< 3.0*10^9/L) occurred in 21/205 (10.2 %) patients with wild type TPMT versus 11/15 (73.3 %) patients with TPMT mutations, p=0.000001. There was no significant difference between TMPT groups in gastrointestinal or other ADRs. No impact of 5-ASA on the incidence and severity of AZA adverse drug reactions was observed. CONCLUSION The incidence of leukopenia in TPMT mutant patients was significantly higher and more severe as compared to TPMT wild type patients. We observed no impact of concomitant 5-ASA therapy on AZA induced toxicity (Tab. 4, Fig. 2, Ref. 37).

[1]  M. Zhu,et al.  Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. , 2010, World journal of gastroenterology.

[2]  W. Newman,et al.  Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? , 2010, Pharmacogenomics.

[3]  R. Ribeiro,et al.  TPMT genetic variations in populations of the Russian Federation , 2009, Pediatric blood & cancer.

[4]  O. Slanař,et al.  Polymorphisms of the TPMT Gene in the Czech Healthy Population and Patients with Inflammatory Bowel Disease , 2008, Nucleosides, nucleotides & nucleic acids.

[5]  W. Bemelman,et al.  European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .

[6]  N. Tosic,et al.  Analysis of Thiopurine S-methyltransferase Polymorphism in the Population of Serbia and Montenegro and Mercaptopurine Therapy Tolerance in Childhood Acute Lymphoblastic Leukemia , 2006, Therapeutic drug monitoring.

[7]  M. Milek,et al.  Thiopurine S-Methyltransferase Pharmacogenetics: Genotype to Phenotype Correlation in the Slovenian Population , 2006, Pharmacology.

[8]  W. Tremaine,et al.  American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[9]  A. Forbes,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.

[10]  D. Hommes,et al.  Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  J. Bierau,et al.  The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients , 2005, Alimentary pharmacology & therapeutics.

[12]  U. Klotz,et al.  Thiopurine S-methyltransferase as a target for drug interactions , 2005, European Journal of Clinical Pharmacology.

[13]  W. Sandborn,et al.  Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines , 2005, Journal of Pharmacology and Experimental Therapeutics.

[14]  C. Peterson,et al.  Assessment of Thiopurine Methyltransferase and Metabolite Formation During Thiopurine Therapy: Results from a Large Swedish Patient Population , 2004, Therapeutic drug monitoring.

[15]  M. Droździk,et al.  Frequency Distribution of Thiopurine S-Methyltransferase Alleles in a Polish Population , 2004, Therapeutic drug monitoring.

[16]  Michel Eichelbaum,et al.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.

[17]  R. Gearry,et al.  Thiopurine S‐methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[18]  J. Belaiche,et al.  Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine , 2003, Alimentary pharmacology & therapeutics.

[19]  M. Neurath,et al.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. , 2003, The Journal of clinical investigation.

[20]  G. Porro,et al.  Alimentary Tract C between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study , 2003 .

[21]  M. Regueiro,et al.  Determination of Thiopurine Methyltransferase Genotype or Phenotype Optimizes Initial Dosing of Azathioprine for the Treatment of Crohn’s Disease , 2002, Journal of clinical gastroenterology.

[22]  A. Hall,et al.  The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. , 2002, Molecular pharmacology.

[23]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[24]  S. Campbell,et al.  Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy , 2001, European journal of gastroenterology & hepatology.

[25]  B. Vainer,et al.  The treatment of inflammatory bowel disease with 6‐mercaptopurine or azathioprine , 2001, Alimentary pharmacology & therapeutics.

[26]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[27]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[28]  W. Evans,et al.  Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. , 1999, Molecular pharmacology.

[29]  R. Modigliani,et al.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.

[30]  G. Fick,et al.  Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.

[31]  R. Weinshilboum,et al.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. , 1995, British journal of clinical pharmacology.

[32]  G. Fick,et al.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.

[33]  M. Kamm,et al.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.

[34]  W. Kalow,et al.  Thiopurine S‐methyltransferase activity in a Chinese population , 1993, Clinical pharmacology and therapeutics.

[35]  B. Korelitz,et al.  The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. , 1990, The American journal of gastroenterology.

[36]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[37]  D. Jewell,et al.  Azathioprine in Ulcerative Colitis: An Interim Report on a Controlled Therapeutic Trial , 1972, British medical journal.